Palatin Technologies Inc (PTN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
59
About the Report
About the Report
Summary
Palatin Technologies Inc (Palatin) is a biopharmaceutical company that undertakes the development of targeted, receptor-specific peptide therapeutics. The company's development programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its clinical pipeline includes melanocortin receptor programs such as Bremelanotide MC4r Agonist for hypoactive sexual desire disorder, PL-8177 MC1r Agonist for inflammatory bowel disease and PL-8331 MC1/5r Agonist for anti-inflammatory ocular indications; and natriuretic peptide receptor programs including PL-3994 NPR-A for heart failure and PL-5028 NPR-A/C Agonist for heart failure and fibrosis. Palatin is headquartered in Cranbury, New Jersey, the US.
Palatin Technologies Inc (PTN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Palatin Technologies Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Palatin Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Palatin Secures USD10 Million Venture Loan from Horizon Technology Finance 11
Licensing Agreements 12
Kwang Dong Pharma Enters into Licensing Agreement with Palatin Technologies 12
Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 13
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 14
Palatin Exercises Option For Licensing Agreement With European Specialty Pharmaceutical Company 16
Equity Offering 17
Palatin Technologies Plans to Raise USD100 Million in Public Offering of Securities 17
Palatin Technologies Plans to Raise up to USD25 Million in Public Offering of Shares 18
Palatin Technologies Raises USD16.5 Million in Public Offering of Units 19
Palatin Technologies Raises USD9.2 Million in Public Offering of Units 21
Palatin Raises USD20 Million in Private Placement of Warrants 23
Palatin Raises USD20 Million in Private Placement of Shares and Warrants 25
Palatin Technologies Completes Private Placement Of Common Stock And Warrants For USD 35 Million 27
Palatin Technologies Inc-Key Competitors 28
Palatin Technologies Inc-Key Employees 29
Palatin Technologies Inc-Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Sep 13, 2018: Palatin Technologies reports fourth quarter and fiscal year 2018 results 31
May 15, 2018: Palatin Technologies Announces Third Quarter Fiscal Year 2018 Results 34
Feb 12, 2018: Palatin Technologies Reports Second Quarter Fiscal Year 2018 Results 36
Nov 13, 2017: Palatin Technologies reports first quarter fiscal year 2018 results 38
Sep 25, 2017: Palatin Technologies Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on September 25, 2017 40
May 16, 2017: Palatin Technologies Reports Third Quarter Fiscal Year 2017 Results 42
Feb 09, 2017: Palatin Technologies Reports Second Quarter Fiscal Year 2017 Results 44
Corporate Communications 45
Sep 12, 2017: Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors 45
Product News 46
01/03/2018: Palatin Technologies Announces FDA Clearance of Investigational New Drug Application for PL-8177 For Ulcerative Colitis 46
Product Approvals 47
Jun 04, 2018: AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide 47
Jun 04, 2018: Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA 49
Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women 50
Clinical Trials 51
May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on its Drug Candidate PL-8177at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts 51
May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on PL-8331 at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts 52
Apr 03, 2018: Palatin Technologies presents preclinical oral formulation data on PL-8177, an investigational melanocortin receptor 1 Agonist for inflammatory bowel disease 53
Feb 05, 2018: Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist 54
Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Women's Sexual Health Annual Meeting 55
Other Significant Developments 57
Jul 11, 2018: Horizon Technology Finance provides investment portfolio update 57
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59
List of Figure
List of Figures
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Palatin Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Palatin Technologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Palatin Secures USD10 Million Venture Loan from Horizon Technology Finance 11
Kwang Dong Pharma Enters into Licensing Agreement with Palatin Technologies 12
Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 13
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 14
Palatin Exercises Option For Licensing Agreement With European Specialty Pharmaceutical Company 16
Palatin Technologies Plans to Raise USD100 Million in Public Offering of Securities 17
Palatin Technologies Plans to Raise up to USD25 Million in Public Offering of Shares 18
Palatin Technologies Raises USD16.5 Million in Public Offering of Units 19
Palatin Technologies Raises USD9.2 Million in Public Offering of Units 21
Palatin Raises USD20 Million in Private Placement of Warrants 23
Palatin Raises USD20 Million in Private Placement of Shares and Warrants 25
Palatin Technologies Completes Private Placement Of Common Stock And Warrants For USD 35 Million 27
Palatin Technologies Inc, Key Competitors 28
Palatin Technologies Inc, Key Employees 29
Palatin Technologies Inc, Subsidiaries 30
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.